Clear Search

Showing 1 result for “Nemec EC”.

July 2022

Efficacy of Subcutaneous Semaglutide Compared to Placebo For Weight Loss in Obese, Non-diabetic Adults: A Systematic Review & Meta-Analysis

Int J Clin Pharm 2022; online ahead of print DOI: 10.1007/s11096-022-01428-1

This systematic review and meta-analysis validates the clinical efficacy of semaglutide for the treatment of obesity in adults without T2D. There is substantial evidence for clinicians to consider modification to their management obese population.

Research of the effect of semaglutide on weight loss has largely focused on T2D, and no meta-analyses in non-diabetic individuals have been conducted to date.

more…